gefitinib has been researched along with Mouth Neoplasms in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (23.81) | 29.6817 |
| 2010's | 9 (42.86) | 24.3611 |
| 2020's | 7 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, BS; Lin, YC | 1 |
| Kim, MS; Yang, SH | 1 |
| Cheng, SJ; Deng, YT; Ko, HH; Kuo, MY; Lee, HC; Lu, YJ; Peng, HH | 1 |
| Cheng, ZY; Chueh, FS; Chung, JG; Hsiao, YT; Lai, KC; Lien, JC; Liu, KC; Peng, SF | 1 |
| Gao, RT; Hua, C; Lv, XX; Ma, HR; Yu, JJ; Zheng, XY | 1 |
| Li, X; Liu, Z; Wang, J; Xu, Y; Yang, Y; Zhang, Y; Zhao, Z | 1 |
| Chen, HM; Chen, HY; Chiang, CP; Li, WC; Lin, HY; Wei, YC; Yang, H | 1 |
| Kannan, S; Sinto, MS; Thomas, S | 1 |
| Jameson, MJ; Khalil, A | 1 |
| Bertrand, D; Chia, S; Chong, FT; DasGupta, R; Gopalakrishna Iyer, N; Hentze, H; Hui Choo, S; Hwang, JSG; Koh, JLY; Kwang, XL; Leong, HS; Lezhava, A; Lim, KH; Low, JL; Periyasamy, G; Sharma, A; Skanthakumar, T; Su, Y; Tan, DSW; Tan, HK; Tan, IBH; Tan, P; Thangavelu, MT; Toh, SY; Zhang, X | 1 |
| Ang, MK; Chang, MM; Chong, FT; Chowbay, B; Chua, BT; DasGupta, R; Iyer, NG; Kwang, XL; Lau, DP; Leong, HS; Lim, TKH; Lim, WT; Sampath, P; Skanderup, AJ; Sundaram, GM; Tan, DSW; Tan, EH; Tan, GS; Toh, SY; Zhang, X | 1 |
| Ashfaq, Z; Bilal, A; Faisal, A; Furqan, M; Huma, Z; Hussain, I; Iqbal, M; Khalid, MH; Nasir, A; Ullah, R | 1 |
| Chan, KK; Furness, S; Glenny, AM; Wakeford, H; Weldon, JC; Worthington, HV | 1 |
| Chavez, J; De La Chapa, JJ; Dybdal-Hargreaves, NF; Gonzales, CB; Horning, AM; Kirma, NB; Parra, J; Saikumar, P; Singha, PK | 1 |
| Amano, O; Chu, Q; Kanda, Y; Kunii, S; Sakagami, H; Wang, Q | 1 |
| Amagaya, S; Chang, CM; Chang, PY; Chen, MY; Jao, HY; Kuo, SC; Lee, CY; Lu, CC; Tu, MG; Yang, JS | 1 |
| Beckler, AD; Carlson, HT; Francom, CR; Jameson, MJ; Khalil, AA; Mendez, RE; Stuart, MM; Taniguchi, LE; Thomas, CY; VanKoevering, KK | 1 |
| Arteaga, CL; Barbieri, CE; Matheny, KE; Pietenpol, JA; Sniezek, JC | 1 |
| Hamakawa, H; Li, C; Mihara, M; Nakashiro, K; Shintani, S; Terakado, N; Yano, J | 2 |
| Purdom, M | 1 |
2 review(s) available for gefitinib and Mouth Neoplasms
| Article | Year |
|---|---|
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Docetaxel; ErbB Receptors; Gefitinib; Humans; Immunotherapy; Lapatinib; Molecular Targeted Therapy; Mouth Neoplasms; Oropharyngeal Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2015 |
Management of acneiform rashes related to gefitinib therapy.
Topics: Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dermatologic Agents; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mouth Neoplasms; Prognosis; Quinazolines; Skin Care | 2004 |
19 other study(ies) available for gefitinib and Mouth Neoplasms
| Article | Year |
|---|---|
Identifying Drug Targets of Oral Squamous Cell Carcinoma through a Systems Biology Method and Genome-Wide Microarray Data for Drug Discovery by Deep Learning and Drug Design Specifications.
Topics: Biomarkers; Biomarkers, Tumor; Carcinoma, Squamous Cell; Deep Learning; Drug Design; Drug Discovery; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Metformin; Mouth Neoplasms; NF-kappa B; Squamous Cell Carcinoma of Head and Neck; Systems Biology | 2022 |
Role of ABCA2 and its single nucleotide polymorphisms (4873T>A and 4879G>C) in the regulation of multi-drug resistance in oral squamous carcinoma cells.
Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gefitinib; HEK293 Cells; Humans; Mouth Neoplasms; Polymorphism, Single Nucleotide | 2023 |
Lysyl oxidase-like 2 promotes stemness and enhances antitumor effects of gefitinib in head and neck cancer via IFIT1 and IFIT3.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mice, SCID; Mouth Neoplasms; Protein-Lysine 6-Oxidase; RNA-Binding Proteins; Squamous Cell Carcinoma of Head and Neck | 2023 |
Gefitinib and curcumin-loaded nanoparticles enhance cell apoptosis in human oral cancer SAS cells in vitro and inhibit SAS cell xenografted tumor in vivo.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Curcumin; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Nanoparticles; Protein Kinase Inhibitors; Xenograft Model Antitumor Assays | 2019 |
EGFR enhances the stemness and progression of oral cancer through inhibiting autophagic degradation of SOX2.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Leupeptins; Macrolides; Male; Mice; Mouth Neoplasms; Mutagenesis; Neoplastic Stem Cells; Protein Kinase Inhibitors; Protein Stability; Proteolysis; SOXB1 Transcription Factors; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2020 |
Novel β-1,3-d-glucan porous microcapsule enveloped folate-functionalized liposomes as a Trojan horse for facilitated oral tumor-targeted co-delivery of chemotherapeutic drugs and quantum dots.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Transport; Cell Survival; Chitosan; Drug Compounding; Drug Liberation; Drug Synergism; Fluorescent Dyes; Folic Acid; Gefitinib; Humans; Liposomes; Male; Mice; Mice, Nude; Mouth Neoplasms; Porosity; Proteoglycans; Quantum Dots; Rats, Sprague-Dawley; Tissue Distribution; Zinc Oxide | 2020 |
Natural Compounds Modulate Drug Transporter Mediated Oral Cancer Treatment.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Catechin; Cell Line, Tumor; Cell Survival; Curcumin; Gefitinib; Humans; Kaplan-Meier Estimate; Mouth Neoplasms; Neoplasm Proteins; Photochemotherapy; Photosensitizing Agents | 2020 |
Combinatorial treatment with Gefitinib and Bay11-7085 sensitizes primary Gefitinib-resistant OSCC cells by influencing the EGFR- NFκB signaling axis.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mouth Neoplasms; NF-kappa B; Protein Kinase Inhibitors; RNA-Seq; Tumor Cells, Cultured | 2021 |
The EGFR Inhibitor Gefitinib Enhanced the Response of Human Oral Squamous Cell Carcinoma to Cisplatin In Vitro.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Mouth Neoplasms; Quinazolines | 2017 |
Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time.
Topics: Adaptor Proteins, Signal Transducing; Animals; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mice, Inbred NOD; Mouth Neoplasms; Phenotype; Phosphoproteins; Precision Medicine; Quinazolines; Transcription Factors; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2017 |
Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gefitinib; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; In Vitro Techniques; Male; Middle Aged; Molecular Targeted Therapy; Mouth Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA Isoforms; RNA Splicing; RNA, Long Noncoding; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2017 |
Identification and evaluation of novel drug combinations of Aurora kinase inhibitor CCT137690 for enhanced efficacy in oral cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Aurora Kinase A; Aurora Kinase B; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Combinations; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Gefitinib; Humans; Imidazoles; Indazoles; Mouth Neoplasms; Nanocapsules; Protein Kinase Inhibitors; Pyridines; Sulfonamides | 2019 |
Co-targeting ALK and EGFR parallel signaling in oral squamous cell carcinoma.
Topics: Anaplastic Lymphoma Kinase; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Mice, Nude; Mouth Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
Tumor-specific cytotoxicity and type of cell death induced by gefitinib in oral squamous cell carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ascorbic Acid; Autophagy; Carcinoma, Squamous Cell; Caspase 3; Cisplatin; Doxorubicin; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Gefitinib; HL-60 Cells; Humans; Methotrexate; Mitoxantrone; Mouth; Mouth Neoplasms; Phytotherapy; Plant Extracts; Quinazolines; Sodium Fluoride; Tumor Cells, Cultured | 2009 |
Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Catechin; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Mouth Neoplasms; Neoplasm Metastasis; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Wound Healing | 2012 |
Activation of the insulin-like growth factor-1 receptor alters p27 regulation by the epidermal growth factor receptor in oral squamous carcinoma cells.
Topics: Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Nucleus; Cyclin D; Cyclin-Dependent Kinase Inhibitor p27; Cytoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Insulin-Like Growth Factor I; Mouth Neoplasms; Oncogene Protein v-akt; Peptide Fragments; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, IGF Type 1; S Phase; Subcellular Fractions | 2013 |
Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Northern; Blotting, Western; Carcinoma, Squamous Cell; Cell Division; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Membrane Proteins; Mouth Neoplasms; Phosphoproteins; Protein-Tyrosine Kinases; Quinazolines; RNA, Messenger; Signal Transduction; Trans-Activators; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2003 |
Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Division; Combined Modality Therapy; Flow Cytometry; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Quinazolines; Reproducibility of Results; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2003 |
Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; G1 Phase; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Quinazolines; S Phase; Tumor Suppressor Proteins; Up-Regulation | 2004 |